


GeneFirst Papilloplex® HPV

The viral E6 and E7 oncogenes are active in cervical carcinomas and their corresponding proteins are directly involved in triggering cell proliferation, inhibition of apoptosis, reprogramming of differentiation, and chromosomal instability leading to malignant transformation of host cells. Transcripts of these oncogenes have always been observed in cervical carcinomas and are used in this assay as a predictive biomarker for the progression of HPV infection to cervical cancer.



The **GeneFirst Papilloplex® HPV tests** are designed for a true molecular HPV screening and triage testing strategy for both clinician and self-collected samples.*



Papilloplex® High Risk mRNA & DNA HPV Assays

- Offer both HPV screening and triage tests to futureproof HPV screening programs and ease of integration into existing programs
- Detection and differentiation of 14 high risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68
- Internal control for sample cellularity and PCR inhibition
- Ease-of-use in a single, multiplex, real-time PCR reaction
- Validated for use with cervical (ThinPrep®) samples
- Validated for use on the Bio-Rad CFX96 and SLAN-96P
- Automated workflow from extraction to qPCR preparation[^]

*EU-VALHUDES conducted as part of a Horizon 2020 SME Instrument Phase 2 Project: HPV OncoPredict ID: 806551

[^] Partner with PrimaDiag, an innovator in robotic platform development www.primadiag.com/en/

Ordering Information

Catalogue No	Product Name	Storage	Intended Use
MPAHPV004	Papilloplex® HR-HPV mRNA	-20° C	CE-IVD (in-vitro diagnostics use)
MPAHPV006	Papilloplex® HR-HPV DNA	-20° C	CE-IVD (in-vitro diagnostics use)



Email: sales@genefirst.com

Web: www.genefirst.com

Accuracy and Sensitivity in Design

Confidence and Clarity in Results

